title: Computational oncology--mathematical modelling of drug regimens for precision medicine.
abstract: Computational oncology is a generic term that encompasses any form of computer-based modelling relating to tumour biology and cancer therapy. Mathematical modelling can be used to probe the pharmacokinetics and pharmacodynamics relationships of the available anticancer agents in order to improve treatment. As a result of the ever-growing numbers of druggable molecular targets and possible drug combinations, obtaining an optimal toxicity-efficacy balance is an increasingly complex task. Consequently, standard empirical approaches to optimizing drug dosing and scheduling in patients are now of limited utility; mathematical modelling can substantially advance this practice through improved rationalization of therapeutic strategies. The implementation of mathematical modelling tools is an emerging trend, but remains largely insufficient to meet clinical needs; at the bedside, anticancer drugs continue to be prescribed and administered according to standard schedules. To shift the therapeutic paradigm towards personalized care, precision medicine in oncology requires powerful new resources for both researchers and clinicians. Mathematical modelling is an attractive approach that could help to refine treatment modalities at all phases of research and development, and in routine patient care. Reviewing preclinical and clinical examples, we highlight the current achievements and limitations with regard to computational modelling of drug regimens, and discuss the potential future implementation of this strategy to achieve precision medicine in oncology.
authors.affiliation: SMARTc Unit, Aix Marseille Université, INSERM, CRO2 UMR_S 911, Marseille 13005, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Barbolosi
authors.affiliation: SMARTc Unit, Aix Marseille Université, INSERM, CRO2 UMR_S 911, Marseille 13005, France.
authors.forename: Joseph
authors.initials: J
authors.lastname: Ciccolini
authors.affiliation: SMARTc Unit, Aix Marseille Université, INSERM, CRO2 UMR_S 911, Marseille 13005, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Lacarelle
authors.affiliation: SMARTc Unit, Aix Marseille Université, INSERM, CRO2 UMR_S 911, Marseille 13005, France.|Multidisciplinary Oncology Unit, Nord University Hospital of Marseille, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille 13000, France.|Centre d'Essais Précoce Cancérologie Marseille (CEPCM), Hospital of La Timone, AP-HM, Marseille 13005, France.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Barlési
authors.affiliation: Aix Marseille Université, INSERM, CRO2 UMR_S 911, Marseille 13005, France.|Department of Paediatric Haematology and Oncology, Hospital of La Timone, AP-HM, Marseille 13005, France.|Centre d'Essais Précoce Cancérologie Marseille (CEPCM), Hospital of La Timone, AP-HM, Marseille 13005, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: André
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D008490:Medical Informatics / Q000379:methods*; D008962:Models, Theoretical; D009369:Neoplasms / Q000188:drug therapy*; D057285:Precision Medicine / Q000379:methods
chemical_list: D000970:Antineoplastic Agents